BCM
TRVI icon

Bridgeway Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Bridgeway Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-44,981
Closed -$246K – 1286
2025
Q2 		$246K Sell
44,981
-35,000
-44% -$218K 0.01% 916
2025
Q1 		$503K Sell
79,981
-97,500
-55% -$465K 0.01% 744
2024
Q4 		$731K Sell
177,481
-8,000
-4% -$25.6K 0.02% 735
2024
Q3 		$620K Hold
185,481
– – 0.01% 810
2024
Q2 		$553K Buy
185,481
+89,000
+92% +$247K 0.01% 836
2024
Q1 		$333K Sell
96,481
-115,000
-54% -$257K 0.01% 1018
2023
Q4 		$283K Buy
211,481
+25,000
+13% +$37.9K 0.01% 1070
2023
Q3 		$407K Hold
186,481
– – 0.01% 937
2023
Q2 		$446K Sell
186,481
-1,919
-1% -$4.83K 0.01% 933
2023
Q1 		$349K Sell
188,400
-20,000
-10% -$45.2K 0.01% 969
2022
Q4 		$402K Buy
208,400
+49,100
+31% +$96.8K 0.01% 932
2022
Q3 		$245K Buy
159,300
+56,700
+55% +$186K 0.01% 1093
2022
Q2 		$288K Buy
102,600
+27,600
+37% +$67.8K 0.01% 1003
2022
Q1 		$165K Hold
75,000
– – ﹤0.01% 1198
2021
Q4 		$59K Buy
75,000
+40,400
+117% +$42.4K ﹤0.01% 1239
2021
Q3 		$47K Hold
34,600
– – ﹤0.01% 1274
2021
Q2 		$78K Sell
34,600
-75,000
-68% -$169K ﹤0.01% 1315
2021
Q1 		$299K Buy
109,600
+9,600
+10% +$28.1K 0.01% 1221
2020
Q4 		$242K Hold
100,000
– – 0.01% 1172
2020
Q3 		$403K Hold
100,000
– – 0.01% 977
2020
Q2 		$658K Buy
100,000
+25,000
+33% +$88K 0.01% 778
2020
Q1 		$247K Hold
75,000
– – 0.01% 994
2019
Q4 		$281K Buy
+75,000
New +$281K ﹤0.01% 1137

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Bridgeway Capital Management's TRVI Position: Q3 2025 in Review

Bridgeway Capital Management sold out of Trevi Therapeutics (TRVI) in Q3 2025, closing a stake of 44,981 shares — an estimated $246K sold.

Bridgeway Capital Management first reported a position in TRVI in Q4 2019 and held it in 23 quarters. The position peaked at $731K in Q4 2024. 164 funds tracked by Wall St. Rank hold TRVI as of Q3 2025.

  • Bridgeway Capital Management reported no remaining Trevi Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bridgeway Capital Management sold 44,981 Trevi Therapeutics shares in Q3 2025, an estimated $246K.
  • Bridgeway Capital Management first reported a position in Trevi Therapeutics in Q4 2019 and held it in 23 quarters.
  • Bridgeway Capital Management's Trevi Therapeutics position peaked at $731K in Q4 2024.
  • 164 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2025.

Based on Bridgeway Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.